| 自体造血干细胞移植治疗恶性淋巴瘤的研究进展 |
| |
| 引用本文： | 孙克盟,闫志凌,桑威.自体造血干细胞移植治疗恶性淋巴瘤的研究进展[J].白血病．淋巴瘤,2017,26(12):765-768. |
| |
| 作者姓名： | 孙克盟 闫志凌 桑威 |
| |
| 作者单位： | 221002,徐州医学院附属医院血液科;221002,徐州医学院附属医院血液科;221002,徐州医学院附属医院血液科 |
| |
| 基金项目： | 国家自然科学基金，江苏省重点研发计划，National Natural Science Foundation of China，Key Research and Development Project of Jiangsu Province |
| |
| 摘 要： | 自体造血干细胞移植(AHSCT)是治疗恶性淋巴瘤(ML)的重要方法,其治疗过程较为复杂,疗效也受诸多因素影响.近年来AHSCT在ML的治疗中应用更加广泛,寻找有效的预后因素以进一步区分可能从AHSCT中获益的患者以及制订合理的移植方案是临床医生关注的重要问题.文章就AHSCT治疗ML的研究进展作一综述.
|
| 关 键 词： | 淋巴瘤 造血干细胞移植 预后 |
Progress of autologous hematopoietic stem cell transplantation for malignant lymphoma treatment |
| |
| Abstract: | Autologous hematopoietic stem cell transplantation (AHSCT) is an important method for treatment of malignant lymphoma. Its treatment process is relatively complex, and the curative effect can be affected by many factors. AHSCT has been widely applied in different subtypes of ML treatment, and looking for effective prognostic factors to further differentiate patients who may benefit from AHSCT and formulating reasonable transplantation are important issues for the clinical doctors to deal with. This article briefly reviews the clinical progress of AHSCT for ML treatment. |
| |
| Keywords: | Lymphoma Hematopoietic stem cell transplantation Prognosis |
| 本文献已被 万方数据 等数据库收录！ |
